- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
USFDA mulls to approve first-ever OTC birth control pill
"This historic application marks a groundbreaking moment in contraceptive access and reproductive equity in the US," said Frederique Welgryn, Chief Strategic Operations and Innovation Officer at HRA Pharma, in the statement.
Washington: Amid the US Supreme Court's decision to ban abortion in the country, the Food and Drug Administration is considering to approve the first-ever over the counter (OTC) birth control pill.
Two companies -- French drugmaker HRA Pharma and US-based Cadence Health -- have approached the FDA to authorise their pill for OTC-sales in the US.
HRA Pharma has applied for an Rx-to-OTC switch for Opill, a progestin - only daily birth control pill (also referred to as a mini pill or non-estrogen pill).
The pill has already been approved for use in the US since 1973, but only with a prescription. If approved, this would be the first daily birth control pill available OTC without a prescription in the US, the company said in a statement.
"This historic application marks a groundbreaking moment in contraceptive access and reproductive equity in the US," said Frederique Welgryn, Chief Strategic Operations and Innovation Officer at HRA Pharma, in the statement.
"More than 60 years ago, prescription birth control pills in the US empowered women to plan if and when they want to get pregnant. Moving a safe and effective prescription birth control pill to OTC will help even more women and people access contraception without facing unnecessary barriers," Welgryn added.
Cadence, whose pill is a combination of progestin and oestrogen plans to submit an application in the coming year, The New York Times reported.
While both companies have been in discussions with the FDA for years, the timing of the HRA Pharma application is "a really sad coincidence," Welgryntold The Times. "Birth control is not a solution for abortion access," she stressed.
The FDA is expected to take around 10 months to make a decision on HRA Pharma's application, media reports said.
Meanwhile, major medical organisations, including the American College of Obstetricians and Gynecologists, the American Medical Association, and the American Academy of Family Physicians, have expressed support for moving birth control pills OTC.
Earlier this year, the US House of Democrats also signed a letter to FDA Commissioner Robert Califf requesting a "timely review" of applications to make birth control pills available OTC, and more than 100 Democrats have signed on to a bill to make health insurance companies cover the cost of OTC birth control, The Times reported.
Read also: Mississippi can't ban pill despite US Supreme Court ruling: Abortion drug maker GenBioPro
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.